Chardan Capital Has Positive Outlook of MCRB FY2025 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Stock analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biotechnology company will post earnings of ($0.57) per share for the year, up from their previous forecast of ($0.73). Chardan Capital has a “Buy” rating and a $1.25 price objective on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($0.38) per share.

MCRB has been the topic of a number of other research reports. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. The Goldman Sachs Group cut their target price on Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $4.00.

Seres Therapeutics Price Performance

Shares of MCRB stock opened at $0.76 on Thursday. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $1.53. The firm’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $0.83. The firm has a market cap of $131.68 million, a P/E ratio of -3.28 and a beta of 2.19.

Hedge Funds Weigh In On Seres Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC raised its position in Seres Therapeutics by 0.6% in the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares during the period. Millennium Management LLC grew its stake in shares of Seres Therapeutics by 77.2% in the fourth quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after buying an additional 788,762 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after buying an additional 121,793 shares during the period. Vontobel Holding Ltd. lifted its position in Seres Therapeutics by 137.6% during the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock worth $780,000 after acquiring an additional 543,469 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock worth $720,000 after acquiring an additional 117,107 shares during the period. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.